Sanofi

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris Other stock markets 07:01:15 2024-06-03 am EDT			5-day change	1st Jan Change
88.92 ^EUR	-0.94%		-1.05%	-0.94%

09:27am	Sanofi Enlists Banks for EUR20 Billion Consumer Health Spinoff, IPO	MT
08:58am	GSK Plans Appeal Against US Judge's Ruling on Jury Trials for Zantac Cases	MT

France's Sanofi Partners With OpenAI to Accelerate Drug Development

May 21, 2024 at 02:02 am EDT

By Mauro Orru

French pharmaceutical company Sanofi is partnering with Sam Altman's OpenAI and AI pharma company Formation Bio to expedite the development of new medicines, tapping artificial intelligence to bring new drugs to the market.

Sanofi said the partnership marked the first collaboration of its kind within the pharma and life sciences industries. The group said it would leverage the partnership to provide access to proprietary data to develop AI models.

"This unique collaboration is the next significant step in our journey to becoming a pharmaceutical company substantially powered by AI," said Sanofi Chief Executive Paul Hudson. "Next generation, first-of-its kind AI model customizations will be an important foundation in our efforts to shape the future of drug development for pharma and for the many patients waiting for innovative treatments."

Write to Mauro Orru at mauro.orru@wsj.com

(END) Dow Jones Newswires

05-21-24 0200ET

Latest news about Sanofi

Sanofi Enlists Banks for EUR20 Billion Consumer Health Spinoff, IPO	03:27am	MT
GSK Plans Appeal Against US Judge's Ruling on Jury Trials for Zantac Cases	02:58am	MT
Sanofi Moving Ahead With EUR20Bln Consumer Healthcare Spinoff, FT Reports	02:40am	DJ
Sanofi Enlists Banks for EUR20 Billion Consumer Health Spinoff, IPO	11:43pm	MT
Delaware judge lets more than 70,000 Zantac lawsuits go forward	Jun. 01	RE
CAC40: at the 8000 pts threshold, loses nearly 1.3% over the week	May. 31	CF
CAC40: remains at equilibrium despite sharp decline in Nasdaq and S&P	May. 31	CF
CAC40: May ends with no trend and a zero score	May. 31	CF
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review	May. 31	RE
Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee	May. 31	MT
Sanofi: launch of employee share ownership plan 2024	May. 31	CF
CAC40: stable trend before US inflation	May. 31	CF
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months	May. 31	MT
Sanofi: positive opinion from the CHMP in COPD	May. 31	CF
CAC40: slightly positive bias before the opening	May. 31	CF
US FDA Delays Decision on Sanofi, Regeneron's Lung Disease Treatment Dupixent	May. 31	MT
Sanofi, Regeneron's Lung Disease Treatment Recommended for EU Approval	May. 31	MT
Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S.	May. 31	DJ
Regeneron Pharmaceuticals, Inc and Sanofi Announce Dupixent® Recommends for EU Approval by the CHMP to Treat Patients with COPD	May. 31	CI
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation	May. 31	CI
CAC40: regains some altitude, Airbus in support	May. 30	CF
Sanofi Closes Purchase of US Biotech Company Inhibrx	May. 30	MT
Sanofi: acquisition of Inhibrx finalized	May. 30	CF
Sanofi Opens New Advanced Vaccines Facility, Strengthening Its Commitment to Biomanufacturing in Canada	May. 30	CI
EU okays $1.5 bln state funded joint hydrogen project, $1.1 bln joint healthcare project	May. 28	RE

Chart Sanofi

Duration

Period

More charts

Company Profile

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release

Related indices

CAC 40 , Euro STOXX 50 Index , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

SANOFI : Sanofi’s healthy Q1 performance hailed by markets

April 25, 2024 at 07:58 am EDT

Sanofi Sees Trend for Years of Steady Growth: CFO

February 03, 2023 at 03:56 pm EST

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

89.76 EUR

Average target price

108.2 EUR

Spread / Average Target

+20.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	-0.94%	122B
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+31.40%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+14.66%	240B
NOVARTIS AG	+9.25%	210B
ROCHE HOLDING AG	-5.07%	206B
AMGEN INC.	+6.17%	164B

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

France's Sanofi Partners With OpenAI to Accelerate Drug Development

EPS Revisions